Rapid Dose Therapeutics Strengthens Leadership Team with Addition of Rodney Butt & Appoints New Advisory Board Member
Retrieved on:
Wednesday, December 15, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Forward-looking statement, Therapy, RDT, Research, WLM, Cannabis, Company, Ontario Medical Association, OMA, Hamilton Academy, Advisory board, Clinical trial, Master of Science, Board, University, COVID-19, Dose, Vaccine, CEO, McMaster University, Department, Drug development, Leadership, Boehringer Ingelheim, Tytus, MBA, CSE, News, Technology, Income tax, CRO, Pharmaceutical industry, Circassia, Bandy
Butt has been involved in all aspects of pharmaceutical drug development, clinical trial design, as well as optimizing organizational design.
Key Points:
- Butt has been involved in all aspects of pharmaceutical drug development, clinical trial design, as well as optimizing organizational design.
- Butt was a member of the Germany-based Clinical Expert Group responsible for managing cardiovascular drug development.
- Butt is a frequent speaker at pharma Industry events and is a lecturer in drug development at the University of Guelph.
- Rapid Dose Therapeutics would also like to confirm their commitment to bringing scientifically sound and medically relevant products to the market with the appointment Dr. Richard Tytus to the Companys Advisory Board.